-+ 0.00%
-+ 0.00%
-+ 0.00%

B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13

Benzinga·03/06/2026 16:21:20
Listen to the news
B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $18 to $13.